.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Voriconazole - Generic Drug Details

« Back to Dashboard
Voriconazole is the generic ingredient in two branded drugs marketed by Glenmark Pharms Ltd, Pf Prism Cv, Amneal Pharms, Aurobindo Pharma Ltd, Mylan Pharms Inc, Zydus Pharms Usa Inc, Versapharm Inc, Prinston Inc, Teva Pharms, Sandoz Inc, Appco Pharma Llc, Novel Labs Inc, Ajanta Pharma Ltd, and Alvogen Inc, and is included in nineteen NDAs. There are two patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

This ingredient has one hundred and nineteen patent family members in fifty-six countries.

There are eleven drug master file entries for voriconazole. Twenty-four suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for Generic Name: voriconazole

Tradenames:2
Patents:2
Applicants:14
NDAs:19
Drug Master File Entries: see list11
Suppliers / Packaging: see list24
Therapeutic Class:Antifungals
Formulation / Manufacturing:see details
Drug Prices:see low prices

Pharmacology for Ingredient: voriconazole

Tentative approvals for VORICONAZOLE

Applicant Application No. Form Dosage
<disabled><disabled>INJECTABLE;INJECTION200MG
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novel Labs Inc
VORICONAZOLE
voriconazole
TABLET;ORAL207371-001May 24, 2016RXNo► subscribe► subscribe
Appco Pharma Llc
VORICONAZOLE
voriconazole
TABLET;ORAL206762-002May 24, 2016RXNo► subscribe► subscribe
Versapharm Inc
VORICONAZOLE
voriconazole
TABLET;ORAL207049-002Sep 7, 2016RXNo► subscribe► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: voriconazole

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pf Prism Cv
VFEND
voriconazole
TABLET;ORAL021266-002May 24, 20025,364,938► subscribe
Pf Prism Cv
VFEND
voriconazole
INJECTABLE;IV (INFUSION)021267-001May 24, 20025,376,645► subscribe
Pf Prism Cv
VFEND
voriconazole
TABLET;ORAL021266-002May 24, 20025,567,817► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: voriconazole

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,773,443 Triazole antifungal agents► subscribe
5,278,175 Triazole antifungal agents► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: voriconazole

Country Document Number Estimated Expiration
Czech Republic289570► subscribe
South Africa9100761► subscribe
Turkey9903191► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: VORICONAZOLE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB02/031United Kingdom► subscribePRODUCT NAME: VORICONAZOLE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/02/212/001-025 20020319
2003005Lithuania► subscribePRODUCT NAME: VORICONAZOLIS; REGISTRATION NO/DATE: 02/7890/8 20021002
C0030France► subscribePRODUCT NAME: VORICONAZOLE; NAT. REGISTRATION NO/DATE: EU/1/02/212/001-025 20020319; FIRST REGISTRATION: EU/1/02/212/001-25 20020319
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc